Amalia Domingo-González

Amalia Domingo-González

Auto-generated profile, based on publicly available information

Amalia Domingo-González

Department of Hematology, Fundación Jiménez Díaz University Hospital, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2020 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RMReyes Maria Martin-Rojas
Reyes Maria Martin-Rojas
GPGloria Pérez‐Rus
Gloria Pérez‐Rus
VDValeria Estefania Delgado‐Pinos
Valeria Estefania Delgado‐Pinos
ADAmalia Domingo‐González
Amalia Domingo‐González
IRIsabel Regalado‐Artamendi
Isabel Regalado‐Artamendi
CPCristina Pascual-Izquierdo
Cristina Pascual-Izquierdo

26 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RRRafael Ríos-Tamayo
Rafael Ríos-Tamayo
RLRamón Lecumberri
Ramón Lecumberri
MLM. Teresa Cibeira López
M. Teresa Cibeira López
VGVerónica González-Calle
Verónica González-Calle
RARafael Alonso
Rafael Alonso
Joan BladéJoan Bladé
Joan Bladé
Systemic AL amyloidosis is a challenging disease for which many patients are considered frail in daily clinical practice. However, no study has so far addressed frailty and its impact on the outcome of these patients. We built a simple score to predict mortality based on three frailty-associated variables: age, ECOG performance status (<2 vs. ≥2) and NT-proBNP (<8500 vs. ≥8500 ng/L). Four-hundred and sixteen consecutive newly diagnosed patients diagnosed at ten sites from the Spanish Myeloma Group were eligible for the study. The score was developed in a derivation cohort from a referral center, and it was externally validated in a multicenter cohort. Multivariate analysis showed that the three variables were independent predictors of survival. The score was able to discriminate four groups of patients in terms of overall survival and early mortality in both cohorts. Comorbidity was also analyzed with the Charlson comorbidity index, but it did not reach statistical significance in the model. A nomogram was created to easily estimate the mortality risk of each patient at each time point. This score is a simple, robust, and efficient approach to dynamically assess frailty-dependent mortality both at diagnosis and throughout follow-up. The optimal treatment for frail AL amyloidosis patients remains to be determined but we suggest that the estimation of frailty-associated risk could complement current staging systems, adding value in clinical decision-making in this complex scenario.

30 July 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
ADAmalia Domingo-González
Amalia Domingo-González
SOSantiago Osorio
Santiago Osorio
ELElena Landete
Elena Landete
SMSilvia Monsalvo
Silvia Monsalvo
JDJose L. Díez-Martín
Jose L. Díez-Martín
Introduction: Methotrexate intoxication following high-dose methotrexate-induced acute kidney injury is a life-threatening complication. Glucarpidase can quickly reduce extracellular methotrexate to safe levels, but the effectiveness and safety of its use in different episodes of nephrotoxicity remain an unknown area. Case Report: A 30-year-old male diagnosed with acute lymphoblastic T-cell lymphoma received methotrexate 5 g/m2 intravenous (IV) as part of the first consolidation cycle. On Consolidation 3, he restarted methotrexate at a dose of 3 g/m2 IV showing slow methotrexate elimination, associated myelosuppression, and hepatic toxicity. Glucarpidase was administered (total dose of 2000 International Units (IU)). No adverse events were observed, and his renal function returned to normal. One hundred and six days later, he was diagnosed with leptomeningeal and cerebellar relapse and treatment with methotrexate 3,5 g/m2 IV day 1 and cytosine arabinoside (Ara-C) 2 g/m2 IV twice per day days 1, 3, and 5 was started. At 36 h from methotrexate infusion, serum creatinine increased up to 1.89 mg/dL and methotrexate concentration was 100 µmol/L. Management and Outcome: Ara-C was suspended, and a second administration of glucarpidase (2000 IU) was dispensed. No adverse events were noticed, methotrexate levels decreased and renal function progressively improved, recovering completely three weeks later. Discussion: The effectiveness and safety of the use of glucarpidase in different episodes of nephrotoxicity remain an unknown area, and the rate and consequences of antiglucarpidase antibody formation remain poorly understood. This case report is, to our knowledge, the first case of a second administration of glucarpidase in a different cycle of high-dose methotrexate in an adult patient.

3 February 2021 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
ADAmalia Domingo‐González
Amalia Domingo‐González
IRIsabel Regalado‐Artamendi
Isabel Regalado‐Artamendi
RMReyes María Martín‐Rojas
Reyes María Martín‐Rojas
GPGloria Pérez‐Rus
Gloria Pérez‐Rus
APAna Pérez‐Corral
Ana Pérez‐Corral
CPCristina Pascual-Izquierdo
Cristina Pascual-Izquierdo

10 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
RRRafael Ríos-Tamayo
Rafael Ríos-Tamayo
RLRamón Lecumberri
Ramón Lecumberri
MLM. Teresa Cibeira López
M. Teresa Cibeira López
VGVerónica González-Calle
Verónica González-Calle
RARafael Alonso
Rafael Alonso
Joan BladéJoan Bladé
Joan Bladé
Systemic AL amyloidosis is a challenging disease for which many patients are considered frail in daily clinical practice. However, no study has so far addressed frailty and its impact on the outcome of these patients. We built a simple score to predict mortality based on three frailty-associated variables: age, ECOG performance status (<2 vs. 2) and NT-proBNP (<8500 vs. 8500 ng/L). Four-hundred and sixteen consecutive newly diagnosed patients diagnosed at ten sites from the Spanish Myeloma Group were eligible for the study. The score was developed in a derivation cohort from a referral center, and it was externally validated in a multicenter cohort. On multivariate analysis the three variables were independent predictors of survival. The score was able to discriminate four groups of patients in terms of overall survival and early mortality in both cohorts. Comorbidity was also analyzed with the Charlson comorbidity index, but it did not reach statistical significance in the model. A nomogram was created to easily estimate the mortality risk of each patient at each time point. This score is a simple, robust, and efficient approach to dynamically assess frailty-dependent mortality both at diagnosis and throughout the follow-up. The optimal treatment for frail AL amyloidosis patients remains to be determined but we suggest that the estimation of frailty-associated risk could complement current staging systems, adding value in clinical decision-making in this complex scenario.

8 September 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ADA. Domingo-González
A. Domingo-González
PCP. Cannata-Ortiz
P. Cannata-Ortiz
RFR. Fernández-Prado
R. Fernández-Prado
AVA. Velasco-Valdazo
A. Velasco-Valdazo
MMM. Menéndez-Cuevas
M. Menéndez-Cuevas
EAE. Askari
E. Askari
Introduction: Current recommendations for hematologic response (HemR) assessment in monoclonal gammopathies of renal significance (MGRS) are based on the monoclonal immunoglobulin (MIg) component responsible for renal damage. Light-chain (LC) amyloidosis criteria are recommended when renal lesions are due to LC, whereas multiple myeloma (MM) criteria are proposed when due to an intact monoclonal immunoglobulin. However, the nephrotoxic MIg is frequently not measurable either by the International Myeloma Working Group (IMWG) or the International Society of Amyloidosis (ISA) criteria. Methods: In the study shown below, we retrospectively analyzed an original multi-center series of 45 MGRS patients. Results: Thirty-two MGRS-non-amyloidosis (MGRS-NA) and 13 MGRS-amyloidosis (MGRS-A) patients were included. Twelve (37.5%) and 15 (47%) MGRS-NA patients had measurable disease by either the IMWG or ISA criteria, respectively. According to the IMWG criteria, 5% of MGRS-NA patients with intact MIg renal deposits and 80% with exclusively LC deposits had measurable disease, as determined by serum electrophoresis or sFLC assay, respectively. Based on the ISA criteria, 35 and 80% of MGRS-NA patients with MIg and LC renal deposits, respectively, had measurable disease. Discussion: Our findings reveal the limitations of the current proposed HemR assessment in MGRS-NA patients and explore potential alternatives to ease clinical practice and guideline development.